Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Laboratoires Fumouze is a historic French pharmaceutical and diagnostic company founded in 1867 by Armand Fumouze. The company is most famous for developing Stérimar, a pioneering seawater-based nasal spray that became a global leader in nasal hygiene. In 2006, the Stérimar brand was acquired by Church & Dwight, while the company's diagnostic division, Fumouze Diagnostics, was eventually integrated into the Groupe Batteur (Laboratoires Gilbert). Today, the Fumouze brand continues to operate as a specialized division focused on rapid diagnostic tests (POCT) for healthcare professionals, covering infectious diseases, immunology, and bacteriology. The company's legacy combines long-standing expertise in consumer health with modern point-of-care diagnostic solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laboratoires Fumouze.